Mitoxantrone and interstitial lung disease Patient Reports February 13, 2012
Mitoxantrone Side Effects Report #5593249-6
Mitoxantrone side effect was reported by a Consumer or non-health professional from CHINA on Dec 27, 2007. Male patient, 71 years of age, weighting 121.3 lb, was diagnosed with prostate cancer
and was treated with Mitoxantrone. After drug was administered, patient experienced the following side effects: anaemia, bronchitis
, condition aggravated, escherichia infection, interstitial lung disease, lobar pneumonia, lung neoplasm, lymphadenopathy mediastinal. Mitoxantrone dosage: 20 MG Q3W IV. During the same period patient was treated with PREDNISONE, NEUPOGEN. Patient died on 10/26/2007.Mitoxantrone Side Effects Report #5614887-8
Mitoxantrone side effect was reported by a Consumer or non-health professional from CHINA on Jan 18, 2008. Male patient, 71 years of age, weighting 121.3 lb, was diagnosed with prostate cancer
and was treated with Mitoxantrone. After drug was administered, patient experienced the following side effects: anaemia, bronchitis
, condition aggravated, escherichia infection, feeling abnormal, interstitial lung disease, lung consolidation, lung infection, lymphadenopathy. Mitoxantrone dosage: 20 MG Q3W IV. During the same period patient was treated with PREDNISONE, NEUPOGEN. Patient died on 10/26/2007.Mitoxantrone Side Effects Report #5281062-9
Mitoxantrone side effect was reported by a Consumer or non-health professional from UNITED STATES on Mar 15, 2007. Female patient, child 5 years of age, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone. After drug was administered, patient experienced the following side effects: blood pressure decreased, interstitial lung disease. Mitoxantrone dosage: 7 MG, 1 IN 1 DAYS, INTRAVENOUS (NOT OTHERWISE SPECIFIED). During the same period patient was treated with CETIRIZINE HYDROCHLORIDE, FLUTICASONE PROPIONATE, DIFLUCAN, OMEPRAZOLE, PERFALGAN, LAXOBERON, ROCEPHALIN, LEVOLAC. Patient was hospitalized. Patient recovered.
Mitoxantrone and interstitial lung disease 